.
MergerLinks Header Logo

New Deal


Announced

Completed

Prime Therapeutics and Magellan Rx Management completed the acquisition of a minority stake in Capital Rx.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

health technology

Medical Services

Acquisition

Minority

Completed

Domestic

Private

Friendly

Synopsis

Edit

Prime Therapeutics and Magellan Rx Management, a pharmacy solutions organization, completed the acquisition of a minority stake in Capital Rx, a health care technology solutions provider. Financial terms were not dsiclosed. “It is imperative for our industry to modernize our technology for the benefit of clients and patients. We evaluated several other platforms and quickly recognized that JUDI represents a new industry standard. This move will enable us to accelerate our pace of innovation while enhancing our core capabilities and ensuring state-of-the-art security. Our ability to utilize JUDI in combination with Prime’s core strengths makes me more confident than ever that Prime will set a new standard for pharmacy solutions,” Mostafa Kamal, Prime President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US